Brief: Kura Oncology And Kyowa Kirin Announce Strategic Collaboration To Develop And Commercialize Ziftomenib In Acute Leukemias
20/11/2024 22:02
Nov 20 (Reuters) - Kyowa Kirin Co Ltd 4151.T :
* KURA ONCOLOGY AND KYOWA KIRIN ANNOUNCE GLOBAL STRATEGIC
COLLABORATION TO DEVELOP AND COMMERCIALIZE ZIFTOMENIB IN ACUTE
LEUKEMIAS
* KURA ONCOLOGY INC - TO RECEIVE $330 MILLION UPFRONT, UP TO
$1.2
BILLION IN MILESTONES
* KURA ONCOLOGY INC - TO INITIATE PHASE 3 FRONTLINE STUDIES
IN AML
IN 2025
Source text: ID:nGNX7fjytx
Further company coverage: 4151.T
Recent news on Kyowa Kirin
See all newsFactbox: Global pharma companies that have publicly announced Trump drug pricing agreements
Factbox: Global pharma companies that have publicly announced Trump drug pricing agreements
Brief: Kyowa Kirin Announces Agreement With US Administration To Reduce Treatment Costs For Americans
Table: Kyowa Kirin 6-MTH group results (IFRS)
Brief: Kyowa Kirin Says European Commission Approves Crysvita For Infants With X-Linked Hypophosphataemia